PURPOSE
For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM).
PATIENTS AND METHODS
The study cohort comprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or ra...
